Abstract Second-generation translocator protein (TSPO) radioligands were developed to circumvent the technical short comings of 11 C-PK11195, the first TSPO targeting tracer. However, in early clinical positron emission tomography (PET) studies they displayed greater inter-and intra-subject variability than was expected given the promising characteristics they showed in preclinical and in vitro studies. A great deal of this variability, although not all, can be explained by the rs6971 polymorphism in the gene encoding TSPO. This polymorphism causes a single amino acid substitution in the TSPO which, for all second-generation tracers tested in man hitherto, reduces binding affinity in mutants relative to wild type. This has obvious implications for interpretation of data, because inter-subject comparisons in PET studies are predicated on the assumption that binding affinity is consistent across all subjects. In this paper, we discuss the implications of the rs6971 polymorphism on study design, analysis and interpretation of data for clinical PET studies using secondgeneration TSPO radioligands.
Introduction
In this issue, Hinz and colleagues describe the modelling challenges involved in quantifying the expression of the 18 kDa translocator protein (TSPO) in the human brain using 11 C-PK11195 [1] . The practical impact of these is to render 11 C-PK11195 studies semi-quantitative only, limiting its use in PET studies aimed at monitoring therapy for clinical or drug development purposes. Some of these challenges are target related; for example, TSPO is expressed throughout the brain and, therefore, the definition of a suitable reference region is problematic. Others are ligand specific.
11 C-PK11195 is hampered by poor signal-to-noise ratio (SNR), with very high nonspecific binding and poor brain extraction. Additionally, 11 C-PK11195 adheres to plastic and glass making accurate plasma measurements difficult and further complicating estimation of the input function. These shortcomings have led to the development of novel high affinity TSPO radioligands with improved SNR relative to 11 C-PK11195 (hereto referred to as second-generation radioligands). Hundreds of potential tracers have been synthesized, though only a handful of promising candidate molecules has been evaluated in man. All second-generation TSPO targeting tracers share an unexpected property that 11 C-PK11195 appears to lack; their binding affinity to the TSPO is altered by a single nucleotide polymorphism (SNP) in the TSPO gene, the frequency of which varies in different populations. Whilst the pre-screening of subjects entering PET studies with a simple genetic test is eminently feasible, it does complicate both the design of studies and the interpretation of PET data obtained with these radioligands. In this paper, we discuss the implications of the rs6971 polymorphism on quantification and study design.
High variability of second-generation TSPO tracer binding 11 C-PBR28, a TSPO ligand from the phenoxyarylacetamide class, was evaluated in man following encouraging preclinical studies which showed that, compared with 11 C-PK11195, it had higher TSPO affinity, lower lipophilicity, and higher specific signal in the CNS [2, 3] . However, in two early clinical studies with healthy volunteers, 4/29 subjects appeared to lack specific binding with 11 C-PBR28 [4, 5] , and there appeared to be no obvious difference in demographics or medical history between the subjects classified as ''binders'' and ''non-binders''. This apparent lack of specific signal had not been reported with 11 C-PK11195 despite 20-year experience with this ligand. Nor was it reported in early studies with other second-generation TSPO ligands, although these studies were characterized by higher than expected inter-subject variability [6, 7] .
Differential binding affinity in vitro, and the rs6971 polymorphism
To explore potential explanations for the phenomenon of non-binding, we performed in vitro radioligand binding studies with post-mortem brain tissue using both 3 H-PBR28 and 3 H-PK11195 [8] . In approximately 50 % of the subjects, these experiments confirmed the higher affinity for the TSPO (K i * 4 vs *30 nM) and lower non-specific binding of 3 H-PBR28 relative to 3 H-PK11195, (f ND * 0.07 vs 0.01 [9] ) In addition to the subjects that we designated high affinity binders (HABs), we detected two further groups. Low affinity binders (LABs), representing 10 % of subjects and exhibiting PBR28-TSPO binding affinity approximately two orders of magnitude lower than HABs (K i * 200 nM). Mixed affinity binders (MABs), representing 40 % of subjects and expressing two TSPO binding sites, which had binding affinities similar to the HAB and LAB sites, respectively. In all 3 groups, however, the TSPO binding affinity for 3 H-PK11195 was consistently estimated at *30 nM. Although we had limited information on the donors, there were no obvious differences in demographics or medical history between these 3 groups.
The relevance of these findings to the interpretation of clinical PET data is self-evident. Assuming these in vitro binding affinity differences occur also in vivo, the implication is that differences in the 11 C-PBR28-specific signal cannot be assumed to reflect differences in TSPO expression alone, but could be due instead to differences in binding affinity. Because of the absence of a detectable signal, LABs are easily identifiable with PET and, therefore, can be eliminated from a cohort. However, HABs and MABs cannot be distinguished by a PET scan and so differences in binding affinity will inflate the variability of 11 C-PBR28 data.
This trimodal distribution in binding affinity was also apparent in all second-generation TSPO targeting radioligands, with no binding affinity class promiscuity (i.e. a sample classified as HAB with 11 C-PBR28 was also classified as HAB with all other ligands). However, there was a wide range in the LAB/HAB affinity ratio across different ligands. PBR28 exhibited the largest affinity ratio (50 fold) whereas most ligands exhibited ratios of approximately 5-10 fold [10, 11] . Whilst the binding affinity for PBR28 in LABs is too low to produce a detectable signal, this is not the case with the other ligands. Since LABs have sufficient affinity with 18 F-PBR06, 11 C-DPA713, 18 F-DPA714 18 F-PBR111 and 11 C-DAA1106 to produce a measurable signal in PET studies, and since the LAB/HAB ratio is smaller than with 11 C-PBR28, the existence of these 3 binding affinity groups has gone undetected with these radioligands hitherto. However, their reduction in affinity in LABs and MABs with respect to HABs means that TSPO expression in these subjects will have been underestimated substantially.
The comparison of ligands produced a further observation: although the absolute affinities in the HAB and LAB subjects differed between ligands, for each ligand the affinities for the two binding sites expressed by the MABs were always very similar to the respective HAB and LAB affinities. In addition, the two sites expressed by MABs were always present in approximately equal proportion. This led to the hypothesis that co-dominant expression of an underlying genetic trait may explain this trimodal distribution of binding affinity. This behaviour could plausibly arise from polymorphisms in either TSPO or other genes encoding proteins which closely associate with TSPO and are thought to modulate its binding parameters. We tested this in a genetic association study and demonstrated perfect concordance between TSPO binding affinity class measured in human platelets with PBR28, and variation at a common polymorphism (rs6971) in the TSPO gene, measured in lymphocytes from the sample subject's blood samples. This finding is highly significant for the interpretation of PET data using second-generation tracers, because it demonstrates that binding affinity class can be predicted by genotyping the TSPO rs6971 polymorphism.
In vivo correlation of rs6971 and PET signal
For TSPO PET studies using second-generation ligands, the in vitro data predict that volume of distribution, V T , values should be of the rank order HAB [ MAB [ LAB, assuming the non-displaceable component (V ND ) is consistent across binding affinity classes. Using 18 F-PBR111 we showed these rank order differences in V T values in all regions of interest [12] . Similar results were reported for V T values obtained with 18 F-FEPPA [13] and 18 F-DPA-714 [14] , and both standardized uptake values (SUV) [15] and V T values [16] obtained with 11 C-PBR28. Using the affinity ratio derived from in vitro studies (R = K d-LAB /K d-HAB , which assumes the HAB and LAB affinities are the same in MABs), it is also possible to estimate the ratio of the binding potential (BP ND ) between the three groups. Assuming that the available TSPO binding site in the MAB is a 50:50 split of the HAB and LAB sites, then;
where :
f ND = free fraction of radioligand in the non-displaceable compartment B avail = concentration of available TSPO binding sites When a ligand shows little selectively between HABs and LABs, as with 11 C-PK11195, R will approach 1 and the expected binding potential will be the same for the three groups. For a highly selective ligand, such as 11 C-PBR28, the influence of the LAB site diminishes and the binding potential in MABs approaches half that of HABs.
Testing these two predictions requires the calculation of BP ND in MABs and HABs for both 11 C-PK11195 and 11 C-PBR28. As BP ND = (V T /V ND ) -1, this requires knowledge of V ND . Given the lack of suitable reference region, this can be achieved either with a blocking study or (in the case of 11 C-PBR28) using the polymorphism plot [12] , which models the difference in the HAB and MAB signals across regions of differing target density.
We tested the predictions for 11 C-PBR28 in a recent blocking study with 11 C-PBR28, using unlabelled XBD173. V ND was estimated to be 1.98 using pharmacological competition data and 2.00 using the polymorphism plot. These V ND estimates produce whole brain BP ND in HABs (1.18 ± 0.15) which, as predicted, was approximately twofold higher than BP ND in MABs (0.48 ± 0.15). Furthermore, a recent blocking study of 11 C-PK11195 with XBD173 in humans showed that the BP ND of HABs and MABs was indeed similar for both groups (around 0.4) [17] .
It is worth considering the possible implications of binding affinity variability beyond TSPO imaging. It was only through serendipity that the effect of the rs6971 polymorphism was revealed; the reduction in LAB affinity with 11 C-PBR28 was so great that it warranted specific investigation (Fig. 1) . If 11 C-PBR28 had not reached a clinical population, the effect of rs6971 would likely have gone unnoticed because the reduction in LAB affinity for the other radioligands is much smaller. However, these radioligands would have consistently and substantially underestimated TSPO expression in both LABs and MABs.
In Vivo: Variability summary for measures
There is no valid reference region available for TSPO in the human brain which has been convincingly demonstrated by heterologous competition studies with the TSPO agent XBD173 [18] . Therefore, V T has typically been chosen as the main outcome measure for the second-generation tracers, although pseudo-reference tissue estimates of DVR and SUVR outcome measures have also been explored.
Estimation of inter-and intra-subject variability in V T for first-and second-generation TSPO tracers demonstrates a higher than expected level of variability even after accounting for the rs6971 polymorphism. Inter-subject variability in the grey matter (restricted to HABs for second-generation tracers) expressed as the %coefficient of 11 C-PK11195 (24 %, [19] ), 18 F-FEPPA (30 %, [13] ), 18 F-PBR111 (35 %, [12] ), 11 C-PBR28 (27 %, [18] ). Similarly, the intra-subject variability is not small; 11 C-PK11195 (13 % [19,]), 11 C-PBR28 (19 % (Owen personal communication), 7 % [20] . The variability of SUV for those ligands is slightly lower than V T (for example 24 % inter-and 8 % intra-subject variability for 11 C-PBR28 (Own observation), which suggests that a large component of the variation in V T could derive from the peripheral blood measures. However, care should be taken in using SUV as it is a non-equilibrium parameter that is also sensitive to blood flow.
If a pseudo-reference region approach (see [21] for a discussion of the principle) is employed using a pseudoreference region with lower signal, but not devoid of TSPO, then variability is dramatically reduced (\10 % for inter-and \5 % for intra-subject variability with 11 C-PBR28), indicating that a large fraction of the variability in V T is derived from the plasma input function. Studies have employed cortical grey matter or cerebellum as a pseudoreference region for TSPO imaging.
TSPO is expressed to some extent by all cellular components of blood [22] . As expected, therefore, recent investigation on the variability of the tracer uptake in the blood demonstrated that there is significant 11 C-PBR28 binding to blood cells, that is also affected by the rs6971 polymorphism in a similar manner to that in the brain (Green, personal communication and Guo, own observation). If there is fast equilibrium for cell binding, then this suggests that the input function should not be restricted to the parent in plasma only and the estimation of the true input function may be more complicated.
There has also been recent work which hypothesizes the existence of a vascular component containing binding to TSPO on the endothelium which may contribute to the variability. However, this hypothesis currently lacks validation and did not demonstrate a significant reduction in variability [23] .
In summary, there is still a significant amount of variability in the V T outcome measure after accounting for the genetic effect, and this variability is similar in magnitude across all second-generation radioligands (%COV *25 %). The variability can be reduced significantly by the use of a pseudo-reference tissue outcome measure such as DVR or SUVR (%COV *5 %) but with the limitation that the binding signal in the pseudo-reference tissue is unknown.
It remains to be established whether this variability reflects inaccuracies in modelling or whether it reflects true variability in expression of TSPO binding sites. For example, it is plausible that TSPO expression may change in response to subtle alterations in oxidative stress or cytokine and steroid concentrations. Furthermore, homopolymerization of TSPO affects radioligand binding and this may also contribute to biological variation. These hypotheses are currently under investigation.
Recommendations for study design
Based on the issues discussed around variability in outcome measures, we make recommendations for clinical PET study designs with second-generation TSPO radioligands.
Genotyping
Although the existence of the rs6971 polymorphism affects the binding affinity of TSPO to certain radioligands, we have found no association between rs6971 genotype and prevalence of neuroinflammatory or neurodegenerative diseases (unpublished). A recent study in mild cognitive impairment patients and Alzheimer's disease also found no difference between genotypes in amyloid load or disease progression [24] . Under the assumption, therefore, the rs6971 genotype does not affect the underlying disease process, this allows for one of the following approaches:
1. Pre-screen subject for genotype and then include only HABs. 2. Pre-screen subject for genotype and then include only HAB and MABs.
Option 1 provides the cleanest population with the highest specific signal, but reduces the ability to recruit subjects for studies. Therefore, the application of option 2, with a suitable correction for binding levels across the genetic groups, may be more appropriate [25] . The frequency of the genotype in the population under investigation (the prevalence of the low-binding allele is 30 % in Caucasians, 25 % in Africans, 2 % in Han Chinese, and 4 % in Japanese) needs also to be considered as this may have a bearing on the approach.
Choice of outcome measure
There are three classes of outcome measure that have been used to quantify PET TSPO studies, each of which has pros and cons;
• V T -dependent on arterial plasma input function and tracer kinetic model.
• SUV-tissue uptake at a chosen time interval.
• DVR/SUVR-pseudo-reference tissue method either based on a reference tissue model, indirect estimation from V T ratio with arterial plasma data or a tissue ratio at a chosen time interval.
V T and SUV allow for assessment of global changes in the signal. However, as we have already highlighted, there is significant variability associated with these measures. Furthermore, whilst V T is theoretically the most quantitative measure, it requires the acquisition of arterial data and also relies on the assumption that the arterial plasma input function as calculated is correct. As discussed in the previous section, the presence of specific binding site in the blood may complicate this assumption. Whilst SUV does not require arterial blood data, it is affected by blood flow and does not always directly correlate with V T . For example, in Lipopolysaccharide (LPS) challenge studies in both non-human primates (NHPs) [26] and humans (Christine Sandiego, personal communication), LPS caused an increases in V T , (driven by a reduction in parent plasma input function), but SUV values in the brain remained the same or lower. Furthermore, within individual PET scans, SUV correlate well with V T . Across scans, however, the relationship between SUV and V T was variable [27] . Similarly, age-related increases in TSPO in NHPs were observed in V T but not SUV (Rajagovindan, personal communication). Therefore, we recommend that when using V T to assess global changes, ideally blocking studies (e.g. with XBD173) should be performed to confirm if the results are driven by TSPO-specific signal changes in the tissue or by peripheral changes.
If the signal under investigation is localized to a particular region and absolute quantification is not required then the relative measures of DVR and SUVR are the methods of choice because of their reduced variability allowing for smaller signals to be detected (although SUVR should be used with additional caution as it is not independent of blood flow). Lyoo et al. have compared using free fraction corrected V T and SUVR (cerebellum as pseudo-reference region) as the outcome measure in temporoparietal lobe in AD patients and healthy controls, and demonstrated that SUVR had a higher sensitivity than V T and, therefore, a smaller sample size would be required with SUVR [25] .
Future directions
Although all new generation TSPO tracers tested hitherto display sensitivity to the rs6971 polymorphism, genotype is easily accounted for and hence these ligands should provide increased performance over 11 C-PK11195 because of their increased specific signal. The fact that in vivo variability is higher than expected for all TSPO tracers (including 11 C-PK11195) demonstrates that further work is required, particularly in understanding whether its source is imperfect modelling of the blood component or true biological variability associated with either BBB transport or central TSPO expression. Because genotyping is straightforward, the residual variability currently represents a much greater limitation to TSPO imaging than rs6971, and therefore development of new tracers which are insensitive to rs6971 would advance the field only marginally. Development of ligands for alternative targets associated with inflammation would also be an important advance for the field.
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